Mostly Markets
Subscribe
Stocks/Health Care/Health Care Equipment

RevvityRVTY

Health Care Equipment · Waltham, Massachusetts · In the S&P 500
Solid businessPricier than peers
$157.00−5.30%After hours: $159.04 (+1.30%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 64.7% over 1 year
Revvity over 1 yearDaily close, $, to 30 Oct 2026
$100$125$150Nov2026MarMayJulSep$157.00$100NovMarJul$157.00
Source: Nasdaq daily closes
Market value$17.52B
Price to earnings74.8x
Forward P/E27.9x
Dividend yield0.18%
Year to date+62.3%
One year+64.7%
Next earningsTue 3 Nov, before the open
SectorHealth Care
52-week range (closes)
$82.26$165.78

Quality and valuation

How Revvity compares with other health care stocks. A description, not a recommendation.

Revvity and 7 health care equipment peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Revvity trades at 27.9 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +4.1% vs +7.8%
  • Less profitable (operating margin): 12.3% vs 13.3%
  • Turns more of its sales into cash: 19.2% vs 15.9%
RVTY trades at 27.9x forward earnings, above the sector medianForward p/e, Health Care Equipment peers
BSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xRVTY27.9xEW29.3xISRG37.5xSector median 19.1xBSX13.8xBDX15.0xMDT16.1xSYK18.4xABT18.6xRVTY27.9xEW29.3xISRG37.5xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 74.8x earnings, RVTY is pricier than its average since Aug 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
40x60x80xAverage 53.8x2025202674.8x50xAverage 53.8x2025202674.8x
Source: Nasdaq prices; SEC filings

Financials

From Revvity's SEC filings, through the quarter ending 5 Jul 2026. Hover or tap a bar for its value.

Revenue grew 1.3% from a year earlierQuarterly revenue, $m, latest Q2 ’26
$0m$200m$400m$600mQ3 ’24Q1 ’25Q3 ’25$730mQ2 ’26$0m$500mQ3 ’24Q1 ’25Q3 ’25$730mQ2 ’26
Source: SEC filings
Growth slowed to +1.3% last quarterRevenue growth, year on year, %
0%2%4%6%Q3 ’24Q1 ’25Q3 ’251.3%Q2 ’260%2%5%Q3 ’24Q1 ’25Q3 ’251.3%Q2 ’26
Source: SEC filings
Operating margin was 12.2% last quarterOperating income as a share of revenue, %
0%5%10%15%Q3 ’24Q1 ’25Q3 ’2512.2%Q2 ’260%10%Q3 ’24Q1 ’25Q3 ’2512.2%Q2 ’26
Source: SEC filings
Free cash flow was $558 million over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$50m$100m$150mQ3 ’24Q1 ’25Q3 ’25$181mQ2 ’26$0m$100mQ3 ’24Q1 ’25Q3 ’25$181mQ2 ’26
Source: SEC filings
Last 12 monthsRVTYSector median
Revenue growth+4.1%+7.8%
Operating margin12.3%13.3%
Free cash flow margin19.2%15.9%
Price to earnings74.8x30.2x

Stories on Revvity

We haven't written about Revvity yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Health Care Equipment, by market value.

CompanyPriceTodayYTDValue
ABTAbbott Laboratories$106.20+1.56%−15.2%$184B
ISRGIntuitive Surgical$432.01−3.73%−23.7%$150B
MDTMedtronic$96.54−0.59%+0.5%$123B
SYKStryker$291.86−6.38%−17.0%$112B
BSXBoston Scientific$41.98−1.66%−56.0%$60.84B
BDXBecton Dickinson$197.88−0.23%+27.4%$53.90B
EWEdwards Lifesciences$92.01−2.57%+7.9%$53.03B
IDXXIdexx Laboratories$551.21−4.30%−18.5%$43.42B